Skip to main content Accessibility help
×
Hostname: page-component-848d4c4894-p2v8j Total loading time: 0 Render date: 2024-05-01T08:16:32.224Z Has data issue: false hasContentIssue false

Chapter 9 - Medical and nutritional management of cholestasis in infants and children

from Section II - Cholestatic liver disease

Published online by Cambridge University Press:  05 March 2014

Andrew P. Feranchak
Affiliation:
Department of Pediatrics, UT Southwestern Medical Center and Children’s Medical Center, Dallas, TX, USA
Frederick J. Suchy
Affiliation:
University of Colorado Medical Center
Ronald J. Sokol
Affiliation:
University of Colorado Medical Center
Frederick J. Suchy
Affiliation:
University of Colorado Medical Center
Ronald J. Sokol
Affiliation:
University of Colorado Medical Center
William F. Balistreri
Affiliation:
University of Cincinnati College of Medicine
Get access

Summary

Introduction

When first encountering an infant or child with cholestatic liver disease, it is essential that diagnostic evaluation be conducted promptly in order to (1) recognize disorders amenable either to specific medical therapy (e.g. galactosemia, tyrosinemia, hypothyroidism, urinary tract infection) or to early surgical intervention (e.g. biliary atresia, choledochal cyst); (2) institute treatment directed toward enhancing bile flow; and (3) prevent and treat the varied medical, nutritional, and emotional consequences of chronic liver disease. Because many of the treatable causes require early diagnosis and prompt institution of therapy, the evaluation of the cholestatic infant should never be delayed. Although “physiologic cholestasis” (hypercholemia or elevated bile acids) may be present in the infant, there is no state of “physiologic conjugated hyperbilirubinemia”. For the jaundiced infant, historical and clinical information such as color of the stools, birth weight, and presence of hepatomegaly may provide important clues as to the etiology of cholestasis. Consanguinity or liver disease in siblings suggests the possibility of metabolic, familial, or genetic disease. Review of the prenatal and postnatal course may reveal intrauterine infection, occurrence of hypoglycemia or seizures, and exposure to toxins/drugs (i.e. total parenteral nutrition (TPN)). Careful physical examination may reveal features of typical disorders or syndromes. For the older child and adolescent, a history of exposure to drugs/toxins (e.g. acetaminophen), the presence of vascular insufficiency, and the presence of underlying disease (e.g. inflammatory bowel disease) provide helpful clues. The diagnostic evaluation of the infant with cholestasis is detailed in Chapter 8.

Type
Chapter
Information
Publisher: Cambridge University Press
Print publication year: 2014

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Sokol, RJ. Medical management of neonatal cholestasis. In Balistreri, WF, Stocker, JT (eds.) Pediatric Hepatology. Philadelphia, PA: Hemisphere, 1990, p. 43.Google Scholar
Suchy, FJ. Neonatal cholestasis. Pediatr Rev 2004;25:388–396.Google ScholarPubMed
Ng, VL, Balistreri, WF. Treatment options for chronic cholestasis in infancy and childhood. Curr Treat Option Gastrol 2005;8:419–430.CrossRefGoogle ScholarPubMed
Maillette de Buy Wenniger, LJ, Oude Elferink, RP, Beuers, U. Molecular targets for the treatment of fibrosing cholangiopathies. Clin Pharmacol Ther 2012;92:381–387.CrossRefGoogle ScholarPubMed
Roma, MG, Toledo, FD, Boaglio, AC, et al. Ursodeoxycholic acid in cholestasis: linking action mechanisms to therapeutic applications. Clin Sci 2011;121:523–544.CrossRefGoogle ScholarPubMed
Beuers, U, Lindor, KD. A major step towards effective treatment evaluation in primary biliary cirrhosis. J Hepatol 2011;55:1178–1180.CrossRefGoogle Scholar
Mendes, F, Lindor, KD. Primary sclerosing cholangitis: overview and update. Nat Rev Gastroenterol Hepatol 2010;7:611–619.CrossRefGoogle ScholarPubMed
Sokol, RJ, Durie, PR. Recommendations for management of liver and biliary tract disease in cystic fibrosis. Cystic Fibrosis Foundation Hepatobiliary Disease Consensus Group. J Pediatr Gastroenterol Nutr 1999;28(Suppl 1):S1–s13.CrossRefGoogle ScholarPubMed
Balistreri, WF. Bile acid therapy in pediatric hepatobiliary disease: the role of ursodeoxycholic acid. J Pediatr Gastroenterol Nutr 1997;24:573–589.CrossRefGoogle ScholarPubMed
Jacquemin, E, Hermans, D, Myara, A, et al. Ursodeoxycholic acid therapy in pediatric patients with progressive familial intrahepatic cholestasis. Hepatology 1997;25:519–523.CrossRefGoogle ScholarPubMed
Jacquemin, E, De Vree, JM, Cresteil, D, et al. The wide spectrum of multidrug resistance 3 deficiency: from neonatal cholestasis to cirrhosis of adulthood. Gastroenterology 2001;120:1448–1458.CrossRefGoogle ScholarPubMed
Sundaram, SS, Bove, KE, Lovell, MA, Sokol, RJ. Mechanisms of disease: Inborn errors of bile acid synthesis. Nature clinical practice. Gastroenterol Hepatol 2008;5:456–468.Google Scholar
Narkewicz, MR, Smith, D, Gregory, C, et al. Effect of ursodeoxycholic acid therapy on hepatic function in children with intrahepatic cholestatic liver disease. J Pediatr Gastroenterol Nutr 1998;26:49–55.CrossRefGoogle ScholarPubMed
Xu, C, Li, CY, Kong, AN. Induction of phase I, II and III drug metabolism/transport by xenobiotics. Arch Pharmacal Res 2005;28:249–268.CrossRefGoogle ScholarPubMed
Ponsioen, CY. Novel developments in IBD-related sclerosing cholangitis. Best practice & research. Clin Gastroenterol 2011;25(Suppl 1):S15–S18.Google Scholar
Meyers, RL, Book, LS, O’Gorman, MA, et al. High-dose steroids, ursodeoxycholic acid, and chronic intravenous antibiotics improve bile flow after Kasai procedure in infants with biliary atresia. J Pediatr Surg 2003;38:406–411.CrossRefGoogle ScholarPubMed
Bergasa, NV. The itch of liver disease. Semin Cutaneous Med Surg 2011;30:93–98.CrossRefGoogle ScholarPubMed
Baghdasaryan, A, Claudel, T, Gumhold, J, et al. Dual farnesoid X receptor/TGR5 agonist INT-767 reduces liver injury in the Mdr2−/− (Abcb4−/−) mouse cholangiopathy model by promoting biliary HCO(−)(3) output. Hepatology 2011;54:1303–1312.CrossRefGoogle Scholar
Hernandez-Gea, V, Friedman, SL. Pathogenesis of liver fibrosis. Ann Rev Pathol 2011;6:425–456.CrossRefGoogle ScholarPubMed
Cohen-Naftaly, M, Friedman, SL. Current status of novel antifibrotic therapies in patients with chronic liver disease. Ther Adv Gastroenterol 2011;4:391–417.CrossRefGoogle ScholarPubMed
Bunchorntavakul, C, Reddy, KR. Pruritus in chronic cholestatic liver disease. Clin Liver Dis 2012;16:331–346.CrossRefGoogle ScholarPubMed
Kremer, AE, van Dijk, R, Leckie, P, et al. Serum autotaxin is increased in pruritus of cholestasis, but not of other origin, and responds to therapeutic interventions. Hepatology 2012;56:1391–1400.CrossRefGoogle Scholar
Imam, MH, Gossard, AA, Sinakos, E, Lindor, KD. Pathogenesis and management of pruritus in cholestatic liver disease. J Gastroenterol Hepatol 2012;27:1150–1158.CrossRefGoogle ScholarPubMed
Kuiper, EM, van Erpecum, KJ, Beuers, U, et al. The potent bile acid sequestrant colesevelam is not effective in cholestatic pruritus: results of a double-blind, randomized, placebo-controlled trial. Hepatology 2010;52:1334–1340.CrossRefGoogle Scholar
Bachs, L, Pares, A, Elena, M, Piera, C, Rodes, J. Comparison of rifampicin with phenobarbitone for treatment of pruritus in biliary cirrhosis. Lancet 1989;i:574–576.CrossRefGoogle Scholar
Yerushalmi, B, Sokol, RJ, Narkewicz, MR, Smith, D, Karrer, FM. Use of rifampin for severe pruritus in children with chronic cholestasis. J Pediatr Gastroenterol Nutr 1999;29:442–447.CrossRefGoogle ScholarPubMed
Wolfhagen, FH, Sternieri, E, Hop, WC, et al. Oral naltrexone treatment for cholestatic pruritus: a double-blind, placebo-controlled study. Gastroenterology 1997;113:1264–1269.CrossRefGoogle ScholarPubMed
Whitington, PF, Whitington, GL. Partial external diversion of bile for the treatment of intractable pruritus associated with intrahepatic cholestasis. Gastroenterology 1988;95:130–136.CrossRefGoogle ScholarPubMed
Ng, VL, Ryckman, FC, Porta, G, et al. Long-term outcome after partial external biliary diversion for intractable pruritus in patients with intrahepatic cholestasis. J Pediatr Gastroenterol Nutr 2000;30:152–156.CrossRefGoogle ScholarPubMed
Swain, MG, Maric, M. Improvement in cholestasis-associated fatigue with a serotonin receptor agonist using a novel rat model of fatigue assessment. Hepatology 1997;25:291–294.CrossRefGoogle ScholarPubMed
Longo, M, Crosignani, A, Podda, M. Hyperlipidemia in chronic cholestatic liver disease. Curr Treat Options Gastroenterol 2001;4:111–114.CrossRefGoogle ScholarPubMed
Simopoulos, AP. Essential fatty acids in health and chronic disease. Am J Clin Nutr 1999;70(3 Suppl):560S–569S.CrossRefGoogle ScholarPubMed
Bucuvalas, JC, Cutfield, W, Horn, J, et al. Resistance to the growth-promoting and metabolic effects of growth hormone in children with chronic liver disease. J Pediatr 1990;117:397–402.CrossRefGoogle ScholarPubMed
Sokol, RJ, Stall, C. Anthropometric evaluation of children with chronic liver disease. Am J Clin Nutr 1990;52:203–208.CrossRefGoogle ScholarPubMed
Sokol, RJ. Fat-soluble vitamins and their importance in patients with cholestatic liver diseases. Gastroenterology Clin North Am 1994;23:673–705.Google ScholarPubMed
Hogler, W, Baumann, U, Kelly, D. Growth and bone health in chronic liver disease and following liver transplantation in children. Pediatr Endocrinol Rev 2010;7:266–274.Google ScholarPubMed
Hogler, W, Baumann, U, Kelly, D. Endocrine and bone metabolic complications in chronic liver disease and after liver transplantation in children. J Pediatr Gastroenterol Nutr 2012;54:313–321.CrossRefGoogle ScholarPubMed
DeRusso, PA, Ye, W, Shepherd, R, et al. Growth failure and outcomes in infants with biliary atresia: a report from the Biliary Atresia Research Consortium. Hepatology 2007;46:1632–1638.CrossRefGoogle ScholarPubMed
Chin, SE, Shepherd, RW, Thomas, BJ, et al. Nutritional support in children with end-stage liver disease: a randomized crossover trial of a branched-chain amino acid supplement. Am J Clin Nutr 1992;56:158–163.CrossRefGoogle ScholarPubMed
Sullivan, JS, Sundaram, SS, Pan, Z, Sokol, RJ. Parenteral nutrition supplementation in biliary atresia patients listed for liver transplantation. Liver Transplant 2012;18:120–128.CrossRefGoogle ScholarPubMed
Shneider, BL, Magee, JC, Bezerra, JA, et al. Efficacy of fat-soluble vitamin supplementation in infants with biliary atresia. Pediatrics 2012;130:e607–e614.CrossRefGoogle ScholarPubMed
Simopoulos, AP, Leaf, A, Salem, N. Essentiality of and recommended dietary intakes for omega-6 and omega-3 fatty acids. Ann Nutr Metab 1999;43:127–130.CrossRefGoogle ScholarPubMed
Feranchak, AP, Gralla, J, King, R, et al. Comparison of indices of vitamin A status in children with chronic liver disease. Hepatology 2005; 42:782–792.CrossRefGoogle ScholarPubMed
Sathe, MN, Patel, AS. Update in pediatrics: focus on fat-soluble vitamins. Nutr Clin Pract 2010;25:340–346.CrossRefGoogle ScholarPubMed
Sokol, RJ, Butler-Simon, N, Conner, C, et al. Multicenter trial of d-alpha-tocopheryl polyethylene glycol 1000 succinate for treatment of vitamin E deficiency in children with chronic cholestasis. Gastroenterology 1993;104:1727–1735.CrossRefGoogle ScholarPubMed
de Albuquerque Taveira, AT, Fernandes, MI, Galvao, LC, et al. Impairment of bone mass development in children with chronic cholestatic liver disease. Clin Endocrinol 2007;66:518–523.Google ScholarPubMed
Strople, J, Lovell, G, Heubi, J. Prevalence of subclinical vitamin K deficiency in cholestatic liver disease. J Pediatr Gastroenterol Nutr 2009;49:78–84.CrossRefGoogle ScholarPubMed
Yanofsky, RA, Jackson, VG, Lilly, JR, et al. The multiple coagulopathies of biliary atresia. Am J Hematol. 1984;16:171–180.CrossRefGoogle ScholarPubMed
Sokol, RJ. Assessing vitamin E status in childhood cholestasis. J Pediatr Gastroenterol Nutr 1987;6:10–13.Google ScholarPubMed
Said, HM. Intestinal absorption of water-soluble vitamins in health and disease. Biochem J 2011;437:357–372.CrossRefGoogle ScholarPubMed
Heubi, JE, Higgins, JV, Argao, EA, Sierra, RI, Specker, BL. The role of magnesium in the pathogenesis of bone disease in childhood cholestatic liver disease: a preliminary report. J Pediatr Gastroenterol Nutr 1997;25:301–306.CrossRefGoogle ScholarPubMed
Umusig-Quitain, P, Gregorio, GV. High incidence of zinc deficiency among Filipino children with compensated and decompensated liver disease. J Gastroenterol Hepatol 2010;25:387–390.CrossRefGoogle ScholarPubMed
Kaller, T, Boeck, A, Sander, K, et al. Cognitive abilities, behaviour and quality of life in children after liver transplantation. Pediatric Transplant 2010;14:496–503.CrossRefGoogle ScholarPubMed
Chin, SE, Shepherd, RW, Thomas, BJ, et al. The nature of malnutrition in children with end-stage liver disease awaiting orthotopic liver transplantation. Am J Clin Nutr 1992;56:164–168.CrossRefGoogle ScholarPubMed
Mattar, RH, Azevedo, RA, Speridiao, PG, et al. [Nutritional status and intestinal iron absorption in children with chronic hepatic disease with and without cholestasis.]. J Pediatr 2005;81:317–324.CrossRefGoogle Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×